Solutions to your working problems

Article

Breaking news from Day 2 of ESCRS

Improving retinal examination speed and efficiency
Canon Europe, revealed its new CX-1, a world first in retinal imaging technology for the first time at this year's ESCRS Congress.

Three steps to better toric surgery
New at congress, Zeiss Toric Solution is a combination of tools to allow physicians to implant and align toric lenses faster and easier.

Megatron S4 from Geuder delivers flexibility and mobility
Geuder has launched the Megatron S4 system, an upgrade on the company’s Megatron S3, which has sold 700 units worldwide since its launch in 2001. “The launch of the S4 marks the successful end of about three years work,”said Dirk Mittnacht, product manager systems for Geuder.

More news from the congressA quartet of solutions for surgeonsAt the sharp endAn all in one optical biometer

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
Related Content
A woman stands at a lectern delivering a presentation to an audience. She is viewed through the blur of the crowded audience. Image credit: ©as-artmedia – stock.adobe.com

Industry preview: Eye care companies announce presentations ahead of ASRS meeting

Sydney M Crago
July 16th 2024
Article

Companies in the retina space announced presentations ahead of the American Society of Retina Specialists meeting, to be held 17-20 July

A person with alopecia areata examines their scalp. Image credit: ©Nadya Kolobova – stock.adobe.com

Alopecia areata and underlying corneal pathologies

Lynda Charters
July 15th 2024
Article

Investigators conducted a case-control study to investigate the corneal topography parameters and biomechanics in patients with alopecia areata

An architectural impression of the Oriel eye health centre exterior. Rendering courtesy Moorfields Eye Charity.

Impact report highlights outcomes of Moorfields Eye Charity programmes

Hattie Hayes
July 12th 2024
Article

The organisation has secured £72.75 million for its new eye health centre

Arrows hit a target on a yellow background. Image credit: ©MclittleStock – stock.adobe.com

VEGF-C and VEGF-D signaling pathways: Potential targets for treating wet AMD

Lynda Charters
July 11th 2024
Article

A novel formulation may prevent blood vessel growth and vascular leakage in the retina

A 2mg branded Ozempic injector. Image credit: ©Fernanda – stock.adobe.com

Semaglutide may be associated with non-arteritic ischemic optic neuropathy (NAION)

Lynda Charters
July 9th 2024
Article

GLP-1 receptor agonists, such as Wegovy, Ozempic and Novo Nordisk, are becoming more prolific

A scientist in a laboratory puts samples into a petri dish. Image credit: ©RFBSIP – stock.adobe.com

Beacon Therapeutics announces new board members, funding to support XLRP and AMD programmes

Martin David Harp
July 8th 2024
Article

The company has secured $170 million (approximately €157 million) in Series B funding

© 2024 MJH Life Sciences

All rights reserved.